Indian Immunologicals to add capacity with Rs 150-cr investment in Telangana
Hyderabad-headquartered biologicals company setting up new viral antigen plant at Karkapatla in Telangana to cater to viral vaccines and opens new sterile filling facility
Hyderabad: Hyderabad-based biologicals company, Indian Immunologicals Ltd (IIL), announced the ground-breaking of a new viral antigen manufacturing facility in Phase III of Genome Valley, Karkapatla, Ranga Reddy District, Telangana. With this investment of Rs 75 crores in the upcoming facility, the company expects to increase its capacity to supply additional quantities of vaccines.
The new facility will be specially designed as a multi-product facility and will cater to the need for viral vaccines in the pipeline that includes Dengue, Zika and Varicella. The company also plans to utilise the facility to manufacture Covid-19 vaccines post completion of its R&D with Griffith University, Australia.
The senior management of the company including Dr K Anand Kumar, MD and Dr Prasanna Deshpande, deputy MD were present during the ground-breaking of the upcoming viral antigen plant.
Spread across 2,000 square meters, the new plant will be designed with the latest biosafety – Biosafety Level 3 suite and will complement Indian Immunologicals’ existing operation adding more equipped and high-speed production.
The company also inaugurated a new sterile filling facility that was commissioned last year at an additional investment of Rs 75 crores. This facility will increase IIL’s capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab.
As a part of the expansion plan, Indian Immunologicals will add over 150 new positions, bringing its total staff strength close to 1,500. The new facility will boost the production capacity by over 35 per cent and increase the supply capacity to key markets where rabies vaccine is critically needed.
Dr K Anand Kumar, MD, Indian Immunologicals said, “As we mark as one of the major players in the pediatric and rabies vaccines, this expansion of our manufacturing facility is our commitment to securing a healthy and sustainable future. The total investment of over Rs 150 crore is in the same direction of our vision to increase the production capacities to ensure a reliable and affordable supply of high-quality vaccines to larger communities.”
“Our new facility is spread across 2,000 square meters and is very well equipped for world class GMP production of Biosafety level 2 and 3 vaccines (BSL-2 and BSL-3). This facility has been specially designed to cater to the need for various viral vaccines and it will boost our manufacturing capacity by 35 per cent. The new plant is expected to be ready for operation by October 2021,” said Dr Prasanna Deshpande, deputy MD, Indian Immunologicals.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
